View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 18, 2021

NIH-funded study to analyse remdesivir for Covid-19 in pregnant women

The US National Institutes of Health has reported that a new study, IMPAACT 2032, will analyse remdesivir in pregnant women who have been prescribed the drug for the treatment of Covid-19. 

The US National Institutes of Health has reported that a new study, IMPAACT 2032, will analyse remdesivir in pregnant women who have been prescribed the drug for the treatment of Covid-19.

The study is funded by the NIH units: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Allergy and Infectious Diseases (NIAID), and the National Institute of Mental Health.

It will be carried out by the NIH-funded International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network at 17 sites in the continental US and Puerto Rico.

The study will analyse the pharmacokinetics of remdesivir. It will also evaluate any potential side effects and adverse events of the drug.

The plasma and umbilical cord samples will be analysed in women who received the drug within five days of delivery to understand remdesivir’s pharmacokinetics in the placenta. Furthermore, breast milk of the lactating women will be tested for the drug.

NICHD director Diana Bianchi said: “Pregnant women with Covid-19 are at high risk for hospitalisation, for intensive care admission, and for needing ventilator support.

“There is an urgent need to identify effective treatments for this population and to determine whether drugs prescribed for other adults are appropriate for use in pregnancy.”

Remdesivir was initially developed for Ebola and Marburg virus treatment. It has demonstrated to speed up recovery in patients with advanced Covid-19 in an NIAID-funded clinical trial.

In addition, it is approved by the US Food and Drug Administration for treating Covid-19 in individuals aged 12 years and above.

At present, the drug is not approved specifically for use in pregnancy but can be prescribed by physicians to pregnant women.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena